AFMD stock news

AFMD earnings call for the period ending June 30, 2019. Read more
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0.00% and -30.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments. Read more
AFMD earnings call for the period ending March 31, 2019. Read more
Clinical stage biotech Affimed N.V. said Wednesday it is terminating its phase I program for AFM11 to focus on its innate immunity portfolio. The company had put two clinical trials of the cancer treatment on hold back in October after one patient died and two others experienced life-threatening events in the high-dose group. The trials were testing the drug in patients with types of non-Hodgkin lymphoma and acute lymphoblastic leukemia. Heidelberg, Germany-based Affimed said it will start a study of AFM13 this year and enter the clinic with AFM24. ""We strongly believe our innate cell engagers could enhance current immuno-oncology approaches and address unmet patient needs in treating hematologic and solid tumor malignancies," Chief Executive Dr. Adi Hoess said in a statement. "We have determined that the optimal use of our resources at this time is to advance our innate cell engagers, focusing their development on indications with high unmet need and the potential for a rapid path to regulatory approval." The company's Chief Scientific Officer Dr. Read more

Affimed reports Q1 results

11:37am, Wednesday, 22'nd May 2019
Read more
Affirmed Therapeutics (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results. Read more
Affirmed Therapeutics (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read more
In trying to determine the current valuation of Affimed N.V. (NasdaqGM:AFMD) shares, we note that the Book to Market ratio of the shares stands at 0.171766. It’s commonly accepted that a Book to Mar Read more
Affimed N.V. (NASDAQ:AFMD) and OncoSec Medical Incorporated (NASDAQ:ONCS) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, analyst recommendations, Read more
At present levels, traders are keeping a close eye on shares of Affimed N.V. (AFMD). During a recent scan, we have spotted Span A above Span B. If this position holds, traders might be anticipating a Read more

Proudly made at